TVARDI THERAPEUTICS, INC. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/5a350811-e562-4ebd-9769-896d545b900b/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-26.7M | 2025-01-01 – 2025-12-31 | evidence 0001104659-26-037729 |
| FY 2024 | $-28.1M | 2024-01-01 – 2024-12-31 | evidence 0001104659-26-037729 |
| FY 2023 | $-121.5M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002609 |
| FY 2022 | $-87.5M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-002913 |
| FY 2021 | $-89.1M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002555 |
| FY 2020 | $5.4M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-001839 |
| FY 2019 | $-111.7M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-001659 |
| FY 2018 | $-77.4M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-007389 |
| FY 2017 | $-59.5M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005879 |
| FY 2016 | $-58.4M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-077107 |
| FY 2015 | $-25.2M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-500345 |
| FY 2014 | $-18.1M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-107249 |
| FY 2013 | $-237.0k | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-107249 |
| FY 2012 | $-6.2M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-107249 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
TVARDI THERAPEUTICS, INC. — all facts · Revenue · Net Income